Bronchiectasis with New Isolation of Pseudomonas aeruginosa in Respiratory Culture: What to Do
Clinical Scenario
This protocol addresses patients with bronchiectasis in whom Pseudomonas aeruginosa has been newly detected on a respiratory culture. This applies whether it represents a patient's first-ever isolation of the organism, or a new isolation following a prolonged interval during which P. aeruginosa was not detected.
Why This Finding Requires Action
A new isolation of Pseudomonas aeruginosa in a patient with bronchiectasis is a clinically significant event that warrants a targeted response. Current guidance supports offering eradication treatment to these patients at this stage.
Treatment Approach (Partial)
Management centres on eradication treatment using antibiotic therapy — delivered in a structured, sequential manner. The complete antibiotic selection, sequencing, and duration are detailed in the full protocol.
The full regimen and monitoring schedule are available via the structured protocol below.
Clinical Goal
The primary therapeutic target is confirmed eradication of Pseudomonas aeruginosa, verified by sputum culture after completion of therapy and reassessed at one year.
References
DOI: 10.1183/13993003.01126-2025
- We suggest to offer eradication treatment to patients with a new isolation of P. aeruginosa.
- A new isolation of P. aeruginosa may refer to the first time a patient has P. aeruginosa isolated or a further isolation following a prolonged period during which P. aeruginosa was not detected.
- The 2017 ERS bronchiectasis guidelines provide examples of antibiotic regimens for eradication which typically consist of 2 weeks of oral or intravenous antibiotics followed by 6 weeks to 3 months of inhaled antibiotics.
- Patients undergoing eradication treatment should have sputum cultures performed after the completion of therapy and at 1 year to confirm whether eradication was successful.
View source ↗